Clinical Management Recommendations

Dermatology and Vaccines: A Call to Arms Shruti Agrawal, Kenneth J Tomecki

PDF 1-3

In-Depth Reviews

Recent Advances in Systemic Therapy for Malignant Melanoma Umair Khan, Shivani Kaushik, Rina Anvekar

PDF 4-14

Clinician-Dermatopathologist Communication via the Requisition Form in the Era of Electronic Medical Records: A Review of the Literature Haley Danielle Heibel, Clay J. Cockerell

PDF 15-22

Characterizing the Skin and Gut Microbiome of Alopecia Areata Patients Margit Juhasz, Siwei Chen, Arash Khosrovi-Eghbal, Chloe Ekelem, Yessica Landaverde, Pierre Baldi, Natasha Atanaskova Mesinkovska

PDF 23-30

Research Letters

A Survey Based Study on the Sun Safety Knowledge of Students Attending Public Schools in San Antonio, TX Venkata Anisha Guda, Sandra Osswald

PDF 31-33

Resident Competition Research Articles

The Perception of Chemotherapy-Induced Alopecia in Cancer Patients Currently Undergoing Treatment Margit Juhasz, Jamie Fortman, Jessica Lin, Yessica Landaverde, Joshua Levy, Christine Pham, Nicole Myers, Chloe Ekelem, Ritesh Parajuli, Lari Wenzel, Natasha Atanaskova Mesinkovska

PDF 34-56

Brief Articles

Subcorneal Pustular Dermatosis Successfully Treated with Acitretin in a Patient with Glucose-6-Phoshate Dehydrogenase Deficiency Mojgan Hosseinipour, Dana Marie Baigrie, Jonathan Crane

PDF 57-61

Lichen Planopilaris Associated with Spray-on Sunscreen Timothy Jay Orlowski, Hoyt Harris Reynolds, Boni Elizabeth Elewski

PDF 62-63

Verrucous Keratoses Associated with Checkpoint Inhibitor Immunotherapy Joshua L Owen, Cory Kosche, Jennifer N Choi

PDF 64-67

A Rare Case of Dermatitis Herpetiformis Presenting as Fingertip Petechiae Amy Weiss, Shiri Nawrocki, Ana Cristina Laureano, Sharon Scherl, Kenneth Shulman, Eun Ji Kwon

PDF 68-71

Dupilumab-Induced Psoriasiform Dermatitis Karlee Novice, Jesse Veenstra, Dana Siegel, Holly Kerr

PDF 72-75

A Case of Kaposi Sarcoma Co-infected with Cytomegalovirus Amena Alkeswani, Allen Oak, Peter Pavlidakey

PDF 76-78

Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Case Report David Dayi Xiong, Brandon Tyler Beal, Manisha Manmohan, Maria Georgina Uberti, Kathryn Riley, Anthony Fernandez

PDF 79-81

Dural-Based Metastatic Malignant Melanoma Masquerading as Meningiomata: A Diagnostic Challenge Mina Zarei, MAHTAB Forouzandeh, Jennifer Ledon, George W Elgart, Jeong Hee Cho-Vega

PDF 82-84

A Case Report of Chilblain Lupus Erythematosus in a Young Male with Literature Review Azib Shahid, Fatima Iftikhar, Katherine Glaser, Anthony Fernandez

PDF 85-91

Spontaneous Resolution of Asymptomatic Papules on the Face of a Two-Year-Old Taylor Shea Novice, Alex Glazer

PDF 92-93

Short Communications

Asymmetric Prurigo Nodularis after Paralysis: A Case Report Justin Chu, Jordan Genece, Yasmin Amir, Mark Lebwohl

PDF 94-96

Secukinumab and Latex Allergies: Don't trust your EMR Yuhan David Gu, Hoyt Harris Reynolds, Rebecca Kissel, Boni E Elewski

PDF 97-99

Compelling Comments

Wes Anderson's "Exceedingly Lovely" Face Erin K. Bartholomew, Mackenzi R. McHugh, Megan C. O'Connor

PDF 100

Dermatologic Etymology: What's in a Name? Paul Regan

PDF 101

Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis

Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction L Green, A Armstrong, CF Teller, S Bell, T Lin

Poster PDF S1

Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study AB Gottlieb, P Gisondi, J Eells, L Peterson, A Kavanaugh

Poster PDF S2

Combination of Calcipotriene 0.05% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis A Young, R Schreiber

Poster PDF S3

Calcipotriene Plus Betamethasone Dipropionate (0.005%/0.064%) foam vs halobetasol propionate and tazarotene (0.01%/0.045%) Lotion: Matching-Adjusted Indirect Comparison & US Cost-Per-Responder Analysis JJ Wu, JB Hansen, DS Patel, NN Jensen, KA Veverka, AR Swensen

Poster PDF S4

Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies A Blauvelt, C Paul, P van de Kerkhof, RB Warren, AB Gottlieb, RG Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich

Poster PDF S5

Demographics, Adherence, and Satisfaction of Home UV Phototherapy in Psoriasis A Pona, A Cline, SS Kolli, SR Feldman

Poster PDF S6

Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials F Cook-Bolden, J Soung, ST Guenthner, B Bumpass, T Lin

Poster PDF S7

Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials SR Desai, B Glick, JQ Del Rosso, T Lin

Poster PDF S8

Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis L Stein-Gold, B Elewski, Z Draelos, T Lin

Poster PDF S9

Efficacy and Safety of Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Moderate to Severe Plaque Psoriasis of the Lower Extremities SK Tyring, LH Kircik, PS Yamauchi, N Anbalagan, T Lin

Poster PDF S10

Novel Lotion Formulation Using Polymeric Emulsion Technology for Improved Skin Moisturization and Drug Permeation in Patients With Psoriasis EA Tanghetti, L Stein-Gold, JQ Del Rosso, S Weiss, T Lin, A Angel, R Pillai

Poster PDF S11

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study MG Lebwohl, J Sugarman, DM Pariser, J Bagel, T Lin, R Israel

Poster PDF S12

Atopic Dermatitis

Study of Adult Atopic Dermatitis and Comorbidities in the US Department of Defense Healthcare System JI Silverberg, L Beck, M Boguniewicz, T Lin, AM Evans, DS Patel, T Rush, AR Swensen

Poster PDF S13

Acne & Rosacea

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials A Moore, L Green, S Bruce, N Sadick, E Tschen, P Werschler, S Dhawan, D Forsha, M Gold, S Guenthner, S Kempers, L Kircik, J Parish, M Rendon, P Rich, L Stein-Gold, S Tyring, R Weiss, A Nasir, C Schmitz, T Boodhoo, A Kaoukhov, D Berk, F Cook-Bolden, Ayman Grada

Poster PDF S14

Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males with Moderate-to-Severe Acne H Baldwin, L Green, L Kircik, E Guenin

Poster PDF S15

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Asians G Han, AW Armstrong, SR Desai, E Guenin

Poster PDF S16

Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability L Stein-Gold, DM Pariser, E Guenin

Poster PDF S17

Efficacy of a Novel Tretinoin 0.05% Lotion in the Treatment of Moderate-to-Severe Acne by Gender and Race: Pooled Analysis of Two Phase 3 Studies E Lain, D Day, JC Harper, E Guenin

Poster PDF S18

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai

Poster PDF S19

Skin Cancer

Integrating the 40-Gene Expression Profile (40-GEP) Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma AS Farberg, MA Hall, L Douglas, KR Covington, SJ Kurley, RW Cook, SM Dinehart

Poster PDF S20

Development and validation of a nomogram incorporating the 31-GEP test and clinicopathologic factors for accurate prediction of recurrence risk in patients with cutaneous melanoma R Thorpe, HG Caruso, KR Covington, D Brodland, J Zitelli

Poster PDF S21

Nail Unit Disorders

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients LF Eichenfield, B Elewski, JL Sugarman, T Rosen, A Gupta, R Pillai, T Lin

Poster PDF S22

Dermatopharmacology

Malignancy Events in Patients With a History of Cancer in Clinical Studies of Brodalumab A Gottlieb, M Lebwohl, A Armstrong, RJ Israel, A Jacobson

Poster PDF S23

One-Year Pharmacovigilance Update of Brodalumab M Lebwohl, C Leonardi, JJ Wu, P Yamauchi, N Rawnsley, M Merchant, A Jacobson

Poster PDF S24

Hyperhidrosis

Treatment Patterns and Depression and Anxiety among Patients Newly Identified with Hyperhidrosis in a Real-World Database Representing US Commercial Health Plan Members M Hull, KK Gillard, J Peterson-Brandt, SZ Klein

Poster PDF S25

Bullous Disease

A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris VP Werth, P Joly, D Mimouni, E Maverakis, P Lahane, L Gearhart, P Pordeli, DM Chen

Poster PDF S26